---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-25-000039"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2025-07-23T23:59:59+00:00"
generated_at: "2026-05-18T03:57:29.653490+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific Q2 net sales $5.06B (+22.8% reported); adj. EPS $0.75 beat guidance; raises FY outlook

## Summary
- GAAP EPS $0.53 ($797M net income) vs $0.22 a year ago; adjusted EPS $0.75 vs guidance $0.71-0.73.
- Q2 organic net sales growth 17.4% (guidance 13-15%); US sales up 30.7% reported.
- Cardiovascular segment grew 26.8% reported; MedSurg up 15.7% reported.
- FY2025 guidance raised: organic growth 14-15%; adjusted EPS $2.95-2.99 (prior $2.82-2.87).
- Closed acquisitions of Intera Oncology and SoniVie; received expanded FDA label for FARAPULSE PFA System.

## SEC filing metadata
- accession: 0000885725-25-000039
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2025-07-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572525000039/0000885725-25-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572525000039/bsx-20250723.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-25-000039
- JSON: https://secwatch.observer/filing/0000885725-25-000039.json
- Plain text: https://secwatch.observer/filing/0000885725-25-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.